Clinical Medicine Insights: Therapeutics

Today the world is facing a high prevalence of dyslipidemia among type II diabetes, and in matter of fact clinical practices against hyperglycemic and hyperlipidemia were quiet intrusive. Our aim was to determine the therapeutic compliance against the clinical practices of dyslipidemia with type II diabetes in a multiracial society. A three year retrospective cohort study was planned to achieve the above mentioned objectives of the study. Study was carried out in out-patient department of General Hospital Penang over a period of ten months (Jan–Oct 2008). Study data collection duration was from Jan 2005–Dec 2007. All the concerned approvals were obtained from Clinical Research Committee (CRC). Data was analyzed by using SPSS 15®. A total of all only 501 diabetes type 2 patients with dyslipidemia were included in this study. The demographic data showed that 55.9% (n = 280) were female patients and 44.1% (n = 221) were male patients. According to racial distribution, Chinese constituted 41.7% of the study population, Malay 34.3% and Indians 24%. The mean age was 62.2 ± 9.2 years. About 56.1% of patients were more and equal than 60 years old range, while 43.9% were in the less or equal range of 59 years. Lifestyle and social habits data demonstrated 86.2% non-smokers, 74.1% with uncontrolled diet and 78.4% on bad exercise. Patients on combination therapy of metformin with other antidiabetic agent were 79%, while 21% were on monotherapy. The test analysis revealed that there was a significant difference between Malay and Chinese in FPG levels, in which the Malay had higher mean FPG than Chinese (mean difference Malay/Chinese 0.75991, P = 0.007). This study showed that both metformin and lovastatin were effective in reducing elevated glucose and lipid values. However, for glucose levels, the values were still above the normal limit used by the hospital. Among the multiracial study population, Chinese had the most controlled HDL levels and Malay had the highest uncontrolled FPG levels. Recommendations were associated with more frequent follow- up and therapeutic monitoring for the patient’s condition by the health practitioners to determine the appropriate compliance with therapy and to control diabetes and dyslipidemia as per needed with therapeutic goals.